Alcon reports positive data with potential Eylea competitor
This article was originally published in Scrip
Executive Summary
Alcon, Novartis's ophthalmic business, has reported positive results from a Phase II study of RTH258, which it is developing to compete against Regeneron Pharmaceuticals' Eylea (aflibercept). RTH258 has already entered Phase III testing.